MLICM
CRL icon

Metropolitan Life Insurance Company (MetLife)’s Charles River Laboratories CRL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,069
Closed -$561K – 505
2024
Q1 		$561K Sell
2,069
-19
-0.9% -$4.54K 0.02% 458
2023
Q4 		$494K Sell
2,088
-33
-2% -$6.49K 0.02% 467
2023
Q3 		$416K Sell
2,121
-109
-5% -$22.4K 0.02% 475
2023
Q2 		$469K Sell
2,230
-45
-2% -$8.95K 0.02% 470
2023
Q1 		$459K Sell
2,275
-668
-23% -$151K 0.02% 477
2022
Q4 		$641K Buy
2,943
+23
+0.8% +$5.02K 0.03% 453
2022
Q3 		$575K Sell
2,920
-33
-1% -$7.12K 0.03% 461
2022
Q2 		$632K Sell
2,953
-56
-2% -$13.7K 0.03% 465
2022
Q1 		$854K Sell
3,009
-4,818
-62% -$1.49M 0.03% 453
2021
Q4 		$2.95M Sell
7,827
-182
-2% -$70.7K 0.04% 370
2021
Q3 		$3.31M Sell
8,009
-252
-3% -$105K 0.05% 314
2021
Q2 		$3.06M Sell
8,261
-3,402
-29% -$1.14M 0.04% 340
2021
Q1 		$3.38M Buy
11,663
+315
+3% +$87.6K 0.05% 318
2020
Q4 		$2.84M Sell
11,348
-266
-2% -$63.4K 0.04% 355
2020
Q3 		$2.63M Sell
11,614
-525
-4% -$109K 0.04% 338
2020
Q2 		$2.12M Sell
12,139
-3,060
-20% -$488K 0.04% 384
2020
Q1 		$1.92M Sell
15,199
-812
-5% -$122K 0.04% 401
2019
Q4 		$2.45M Buy
16,011
+23
+0.1% +$3.19K 0.04% 439
2019
Q3 		$2.12M Buy
15,988
+408
+3% +$54.7K 0.04% 483
2019
Q2 		$2.21M Buy
15,580
+84
+0.5% +$11.4K 0.04% 480
2019
Q1 		$2.25M Sell
15,496
-28
-0.2% -$3.68K 0.04% 426
2018
Q4 		$1.76M Buy
15,524
+43
+0.3% +$5.38K 0.04% 500
2018
Q3 		$2.08M Sell
15,481
-78
-0.5% -$9.63K 0.04% 501
2018
Q2 		$1.75M Sell
15,559
-276
-2% -$29.8K 0.03% 596
2018
Q1 		$1.69M Buy
15,835
+118
+0.8% +$12.7K 0.02% 638
2017
Q4 		$1.72M Sell
15,717
-31,185
-66% -$3.39M 0.02% 628
2017
Q3 		$5.07M Sell
46,902
-8
-0% -$822 0.03% 580
2017
Q2 		$4.75M Buy
46,910
+912
+2% +$83.9K 0.03% 610
2017
Q1 		$4.14M Sell
45,998
-74
-0.2% -$6.29K 0.03% 690
2016
Q4 		$3.51M Sell
46,072
-252
-0.5% -$19.1K 0.03% 753
2016
Q3 		$3.86M Sell
46,324
-109
-0.2% -$9.14K 0.03% 686
2016
Q2 		$3.83M Buy
46,433
+1,904
+4% +$157K 0.03% 662
2016
Q1 		$3.38M Buy
44,529
+1,278
+3% +$94.6K 0.03% 699
2015
Q4 		$3.48M Buy
43,251
+132
+0.3% +$9.52K 0.03% 662
2015
Q3 		$2.74M Sell
43,119
-856
-2% -$61.5K 0.02% 777
2015
Q2 		$3.09M Buy
43,975
+1,301
+3% +$96.3K 0.02% 774
2015
Q1 		$3.38M Buy
42,674
+1,778
+4% +$131K 0.02% 694
2014
Q4 		$2.6M Buy
40,896
+588
+1% +$36.9K 0.02% 860
2014
Q3 		$2.41M Sell
40,308
-1,093
-3% -$62.5K 0.02% 870
2014
Q2 		$2.22M Buy
41,401
+680
+2% +$37.3K 0.02% 960
2014
Q1 		$2.46M Buy
40,721
+393
+1% +$22.9K 0.02% 873
2013
Q4 		$2.14M Sell
40,328
-583
-1% -$29.3K 0.02% 942
2013
Q3 		$1.89M Buy
40,911
+524
+1% +$24K 0.01% 963
2013
Q2 		$1.66M Buy
+40,387
New +$1.73M 0.01% 979

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CRL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 2,069 shares — an estimated $561K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CRL in Q2 2013 and held it in 44 quarters. The position peaked at $5.07M in Q3 2017. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,069 Charles River Laboratories shares in Q2 2024, an estimated $561K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Charles River Laboratories in Q2 2013 and held it in 44 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Charles River Laboratories position peaked at $5.07M in Q3 2017.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.